N-(exo-(Hexahydro-1H-pyrrolizine-1-yl)methyl)-2-methoxy-4-amino-5-chlorobenzamide | 146388-57-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(exo-(Hexahydro-1H-pyrrolizine-1-yl)methyl)-2-methoxy-4-amino-5-chlorobenzamide
• 英文别名: 4-amino-5-chloro-N-(2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-ylmethyl)-2-methoxybenzamide;hydrochloride
• CAS: 146388-57-0
• 化学式: C16H23Cl2N3O2
• 分子量: 360.3
• InChiKey: TVWDAUMNWKAMIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.57
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  67.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
  申请人：Compan Valerie

  公开号：US20060116341A1

  公开（公告）日：2006-06-01

  This invention relates to the use of a ligand of the 5-HT 4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT 4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT 4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT 4 receptor or of a functionally equivalent receptor.

  本发明涉及一种 5-HT 4 受体的配体或该配体的药学上可接受的盐，以及编码 5-HT 4 受体或功能等效受体的核酸，用于治疗和/或预防与强迫行为有关的病理，如厌食症、贪食症和滥用药物成瘾或肥胖症。本发明还涉及一种鉴定化合物的方法，该化合物在治疗和/或预防与强迫行为或肥胖症相关的病理方面具有生物活性，包括：a) 将 5-HT 4 受体或功能相当的受体与这种生物活性化合物接触，以及 b) 确定这种生物活性化合物是否能够调节 5-HT 4 受体或功能相当的受体的基础活性。
• PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY
  申请人：Compan Valerie

  公开号：US20090124592A1

  公开（公告）日：2009-05-14

  This invention relates to the use of a ligand of the 5-HT 4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT 4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT 4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT 4 receptor or of a functionally equivalent receptor.
• US8436021B2
  申请人：——

  公开号：US8436021B2

  公开（公告）日：2013-05-07
• US8859537B2
  申请人：——

  公开号：US8859537B2

  公开（公告）日：2014-10-14
• US9168250B2
  申请人：——

  公开号：US9168250B2

  公开（公告）日：2015-10-27